Replimune Group, Inc. — FY2023 Form 10-K
Period clarification: This filing covers the fiscal year ended March 31, 2023, not calendar-year 2022 Q4. The company is a clinical-stage biotechnology company developing oncolytic immunotherapies; it had no approved products and generated no product sales revenue.
Financial performance and liquidity
| Metric | FY ended Mar. 31, 2023 | FY ended Mar. 31, 2022 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $126.5 million | $79.5 million |
| Selling, general and administrative expense | $50.6 million | $38.8 million |
| Operating loss | $177.1 million | $118.3 million |
| Net loss | $174.3 million | $118.0 million |
| Net loss per share, basic and diluted | $2.99 | $2.26 |
| Net cash used in operating activities | $128.1 million | $82.2 million |
At March 31, 2023, cash and cash equivalents were $146.6 million and short-term investments were $436.8 million, totaling $583.4 million. Management estimated these resources would fund planned operations into the second half of calendar 2025, based on current plans and assumptions. Current assets were $592.6 million and current liabilities were $33.8 million. No product-sales margin is reported because there were no product sales.
Long-term debt had a $30.2 million principal balance and a $28.6 million carrying value, net of discounts, at year-end. The Hercules facility permits up to $200 million in multiple tranches; the company had drawn an initial $30 million. Interest is floating, with a 7.25% floor plus 1.50% payment-in-kind interest. The loan includes cash and other financial covenants. Lease liabilities totaled $32.1 million; undiscounted future lease payments were approximately $56.6 million.
Changes from the prior year
- Net loss increased 48%, primarily as operating expenses rose 50%. R&D expense increased 59%, reflecting broader development activity, manufacturing transfer and validation work, and increased RP1 trial costs. SG&A expense increased 30%, including pre-commercial planning and commercial infrastructure spending.
- Operating cash use rose to $128.1 million from $82.2 million. The company raised substantial capital: financing cash flow was $311.3 million, including common stock and pre-funded warrant offerings, ATM sales, and Hercules borrowing.
- Investment income increased to $10.0 million from $0.4 million, partly offset by $5.7 million of foreign-currency expense and $2.0 million of debt interest expense.
- Regeneron reimbursements for CERPASS costs under the initial study plan ended in the period to June 30, 2022; the company expected no further reimbursement under that plan.
Programs, outlook and key risks
- RP1: CERPASS, a registration-directed Phase 2 trial in locally advanced or metastatic cutaneous squamous cell carcinoma, enrolled 211 randomized patients. Topline data were expected in Q3 2023; subject to positive data demonstrating overall clinical benefit, the company expected to submit a BLA in Q1 2024. The FDA had discussed the study design and emphasized that the totality of data must show a clinically meaningful benefit.
- RP1 melanoma: The IGNYTE registration-directed cohort completed enrollment with 141 patients. A data snapshot for all patients, each with at least six months’ follow-up, was expected in Q4 2023; topline primary-analysis data were expected in Q2 2024. Previously reported investigator-assessed data from the first 75 patients showed a 20% complete response rate and 36% overall response rate; these were interim results, not final trial outcomes.
- RP2 and RP3: Phase 1 enrollment was expected to be substantially complete in Q3 2023, with planned signal-finding Phase 2 studies around mid-2023 in head and neck, liver and colorectal cancers, including combinations supplied or supported through BMS and Roche collaborations.
- Manufacturing: The Framingham facility was operational, and comparability work for RP1, RP2 and RP3 was complete. The company cited continued risks around facility qualification, reliable production, raw-material supply, costs and regulatory acceptance.
- Principal risks: Clinical efficacy, safety and enrollment uncertainty; regulatory approval and possible confirmatory-trial requirements; need for additional capital; execution of in-house manufacturing; dependence on collaborators and suppliers; competition and reimbursement uncertainty; and intellectual-property challenges. The company had petitioned for inter partes review of an Amgen patent it believed was improperly issued. It reported no material legal proceedings.
- Other notable matters: The company disclosed risks from uninsured bank balances; it had accessed all funds held at Silicon Valley Bank after the FDIC intervention. Its CFO had notified the company of her resignation, effective June 2, 2023. Management reported effective disclosure controls and internal control over financial reporting; the external auditor did not audit internal control effectiveness.
Investor verification checklist
- Confirm subsequent CERPASS results, their statistical and clinical significance, and any FDA feedback on whether they support a BLA.
- Verify actual RP1 melanoma data and regulatory plans against the interim figures and timelines disclosed in the filing.
- Track cash burn, financing needs and dilution, including the Hercules facility’s draw conditions and covenants, ATM capacity, and outstanding pre-funded warrants.
- Assess whether the Framingham facility can consistently supply trials and future commercial needs, and whether collaborators continue to provide drugs and cost-sharing as expected.
- Review subsequent filings for changes to trial schedules, leadership, intellectual-property proceedings, and management’s cash-runway assumptions.